Analysis of PIK3CA and B-RAF gene mutations in human astrocytomas: Association with activation of ERK and AKT

Clinical Neuropathology

Volumn 29, Issue 4, 2010, Pages 239-245

  El Habr, E A ^a   Tsiorva, P ^a   Theodorou, M ^a   Levidou, G ^a   Korkolopoulou, P ^a   Vretakos, G ^b   Petraki, L ^b   Michalopoulos, N V ^a   Patsouris, E ^a   Saetta, A A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b METROPOLITAN HOSPITAL   (Greece)

Author keywords

Astrocytomas; B RAF mutation; pAKT expression immunohistochemistry; pERK expression; PIK3CA mutation

Indexed keywords

B RAF KINASE; GENOMIC DNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; BRAF PROTEIN, HUMAN; PIK3CA PROTEIN, HUMAN;

ARTICLE; ASTROCYTOMA; BRAIN TUMOR; DISEASE ASSOCIATION; ENZYME ACTIVATION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM; COHORT ANALYSIS; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ASTROCYTOMA; BRAIN NEOPLASMS; COHORT STUDIES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MAP KINASE SIGNALING SYSTEM; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 77954638433     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.5414/npp29239     Document Type: Article

References (41)

1. Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Roselló J, Nicholson RI, Mendelsohn J, Baselga J. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res. 2001; 61: 6500-6510.
2. Basto D, Trovisco V, Lopes JM, Martins A, Pardal F, Soares P, Reis RM. Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathol (Berl). 2005; 109: 207-210.
3. Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, Ferrandina G, Benedetti Panici P, Mancuso S, Neri G, Testa JR. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer. 1995; 64: 280-285.
4. Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, McLendon RE, Fults DW, Velculescu VE, Bigner DD, Yan H. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res. 2004; 64: 5048-5050. (Pubitemid 39006515)
5. Burger M, Denzinger S, Hammerschmied C, Tannapfel A, Maderstorfer A, Wieland WF, Hartmann A, Stoehr R. Mitogen-activated protein kiase signaling is activated in prostate tumors but not mediated by B-RAF mutations. Eur Urol. 2006; 50: 1102-1109.
6. Chakravarti A, Zhai G, Suzuki Y, Sarkesh S, Black PM, Muzikansky A, Loeffler JS. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol. 2004; 22: 1926-1933. (Pubitemid 41095185)
7. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature. 2002; 417: 949-954.
8. Gallia GL, Rand V, Siu IM, Eberhart CG, James CD, Marie SK, Oba-Shinjo SM, Carlotti CG, Caballero OL, Simpson AJ, Brock MV, Massion PP, Carson BS Sr, Riggins GJ. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res. 2006; 4: 709-714.
9. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr, Weber MJ. Activation of mitogen activated protein kinase associated with prostate cancer progression. Cancer Res 1999; 59: 279-284. (Pubitemid 29048852)
10. Hanahan D, Weinberg RA. The hall marks of cancer. Cell. 2000; 100: 57-70.
11. Hartmann C, Bartels G, Gehlhaar C, Holtkamp N, von Deimling A. PIK3CA mutations in glioblastoma multiforme. Acta Neuropathol. 2005; 109: 639-642.
12. Hay N. The AKT-mTOR tango and its relevance to cancer. Cancer Cell. 2005; 8: 179-183. (Pubitemid 41317589)
13. Holland EC. A mouse model for glioma: biology, pathology, and therapeutic opportunities. Toxicol Pathol. 2000; 28: 171-177.
14. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M. Constitutive activation of the 41- /43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene. 1999; 18: 813-822.
15. Jeuken J, van den Broecke C, Gijsen S, Boots-Sprenger S, Wesseling P. RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathol. 2007; 114: 121-133. (Pubitemid 47103523)
16. Jørgensen K, Holm R, Maelandsmo GM, Flørenes VA. Expression of activated extracellular signal-regulated kinases 1/2 in malignant melanomas: relationship with clinical outcome. Clin Cancer Res. 2003; 9: 5325-5331.
17. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer. 2006; 94: 455-459. (Pubitemid 43289745)
18. Karlou M, Saetta AA, Korkolopoulou P, Levidou G, Papanastasiou P, Boltetsou E, Isaiadis D, Pavlopoulos P, Thymara I, Thomas-Tsagli E, Patsouris E. Activation of extracellular regulated kinases (ERK1/2) predicts poor prognosis in urothelial bladder carcinoma and is not associated with B-Raf gene mutations. Pathology. 2009; 41: 327-334.
19. Kita D, Yonekawa Y, Weller M, Ohgaki H. PIK3CA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathol. 2007; 113: 295-302. (Pubitemid 46443564)
20. Knobbe CB, Reifenberger J, Reifenberger G. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol. 2004; 108: 467-470. (Pubitemid 39534587)
21. Knobbe CB, Trampe-Kieslich A, Reifenberger G. Genetic alteration and expression of the phosphoinositol-3-kinase/AKT path way genes PIK3CA and PIKE in human glioblastomas. Neuropathol Appl Neurobiol. 2005; 31: 486-490. (Pubitemid 41337782)
22. Kondo Y, Hollingsworth EF, Kondo S. Molecular targeting for malignant gliomas. Int J Oncol. 2004; 24: 1101-1109.
23. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat. 2008; 11: 32-50.
24. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114: 97-109. (Pubitemid 47103521)
25. Manning BD, Cantley LC. AKT/PKB signaling: navigating down stream. Cell. 2007; 129: 1261-1274.
26. Mirza AM, Gysin S, Malek N, Nakayama K, Roberts JM, McMahon M. Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT. Mol Cell Biol. 2004; 24: 10868-10881. (Pubitemid 39603142)
27. Mizumoto Y, Kyo S, Mori N, Sakaguchi J, Ohno S, Maida Y, Hashimoto M, Takakura M, Inoue M. Activation of ERK1/2 occurs in dependently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis. Cancer Sci. 2007; 98: 652-658. (Pubitemid 46563440)
28. Mori N, Kyo S, Sakaguchi J, Mizumoto Y, Ohno S, Maida Y, Hashimoto M, Takakura M, Inoue M. Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs in dependently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosiss. Cancer Sci. 2007; 98: 1881-1888.
29. Mueller W, Mizoguchi M, Silen E, D'Amore K, Nutt CL, Louis DN. Mutations of the PIK3CA gene are rare in human glioblastoma. Acta Neuropathol (Berl). 2005; 109: 654-655. (Pubitemid 40974155)
30. Nishimoto S, Nishida E. MAPK signalling: ERK5 versus ERK1/2. EMBO Rep 2006; 7: 782-786. (Pubitemid 44275395)
31. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001; 22: 153-183. (Pubitemid 32458157)
32. Pelloski CE, Lin E, Zhang L, Yung WK, Colman H, Liu JL, Woo SY, Heimberger AB, Suki D, Prados M, Chang S, Barker FG 3rd, Fuller GN, Aldape KD. Prognostic associations of activated mitogen- activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res. 2006; 12: 3935-3941.
33. Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, Bernet V, Burman KD, Kohn LD, Saji M. Overexpression and overactivation of AKT in thyroid carcinoma. Cancer Res. 2001; 61: 6105-6111.
34. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004; 304: 554. (Pubitemid 38541907)
35. Schmitz KJ, Wohlschlaeger J, Alakus H, Bohr J, Stauder MA, Worm K, Winde G, Schmid KW, Baba HA. Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations. Virchows Arch. 2007; 450: 151-159.
36. Shrieve DC, Alexander E 3rd, Black PM, Wen PY, Fine HA, Kooy HM, Loeffler JS. Treatment of patients with primary glioblastoma multiforme with standard post operative radiotherapy and radio surgical boost: prognostic factors and long-term outcome. J Neurosurg. 1999; 90: 72-77.
37. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV, Cheng JQ. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol. 2001; 15: 431-437.
38. Velasco A, Bussaglia E, Pallares J, Dolcet X, Llobet D, Encinas M, Llecha N, Palacios J, Prat J, Matias-Guiu X. PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and KRAS alterations. Hum Pathol. 2006; 37: 1465-1472.
39. Vicent S, López-Picazo JM, Toledo G, Lozano MD, Torre W, Garcia-Corchón C, Quero C, Soria JC, Martín-Algarra S, Manzano RG, Montuenga LM. ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br J Cancer. 2004; 90: 1047-1052.
40. Wang H, Wang H, Zhang W, Huang HJ, Liao WS, Fuller GN. Analysis of the activation status of AKT, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest. 2004; 84: 941-951.
41. Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors. 2006; 24: 21-44. (Pubitemid 43108774)